Question 1

What is DEPEMOKIMAB used for?

Accepted Answer

DEPEMOKIMAB (brand name Exdensur) is a Other indicated for See full prescribing information.

Question 2

How does DEPEMOKIMAB work?

Accepted Answer

DEPEMOKIMAB works through the following mechanism: 12.1 Mechanism of Action Depemokimab‑ulaa is an IL‑5 antagonist (humanized IgG1 kappa monoclonal antibody), which binds to IL‑5 with a dissociation constant of 10.5 pM, inhibiting the bioactivity of IL‑5 with in vitro IC50 value of 4 pM by blocking its binding to the alpha chain of the IL‑5 receptor complex expressed on the cell surface. Depemokimab‑ulaa contains a triple amino acid substitution (YTE) in the fragment crystallizable (Fc) region which increases binding to the neonatal Fc receptor and thereby extends the elimination half‑life. These properties support the dosing interval of every 6 months. IL‑5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation..

Question 3

What are the most common side effects of DEPEMOKIMAB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for DEPEMOKIMAB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is DEPEMOKIMAB the same as Exdensur?

Accepted Answer

Exdensur is a brand name for DEPEMOKIMAB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

DEPEMOKIMAB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations